Cytokinetics (CYTK) said Friday that European Medicines Agency's Committee for Medicinal Products for Human Use has recommended a marketing authorization for Myqorzo for the treatment of obstructive hypertrophic cardiomyopathy in adults.
A final decision on the marketing authorization is expected from the European Commission in Q1 of 2026, Cytokinetics said.